The funding will support the British Columbia Cancer Agency's effort to use genome sequencing to develop personalized treatment strategies for cancer patients.
Among 100 adults and six children recruited between June 2012 and August 2014, most were successfully sequenced and a majority of those had actionable results.
Researchers leading the POG trial are hoping this year to sequence the whole genomes of 300 cancer patients in an effort to find the best treatment options for them.
The goal is to analyze a variety of genomic techniques, including sequencing, to develop a test that will determine whether AML patients should receive chemotherapy or stem cell transplantation.
The Genome British Columbia program will kick off with funding totaling around $9 million for three personalized medicine studies.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.